Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Enterprise Cost Realignment Program (2023–2027) by Quarter
Enterprise Cost Realignment Program (2023–2027) — Cumulative costs incurred to date ($M) ($M)
Pfizer Enterprise Cost Realignment Program (2023–2027): $4,900M in Q2 2026, up 40.0% from a year earlier. That is the highest of the 11 quarters on record here.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Note 3 — Restructuring Charges & Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Enterprise Cost Realignment Program (2023–2027) — Cumulative costs incurred to date ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 28, 2026 | 4,900 | +40.0% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 29, 2026 | 4,300 | +34.4% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 4,200 | +61.5% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 28, 2025 | 3,700 | +105.6% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 29, 2025 | 3,500 | +133.3% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 30, 2025 | 3,200 | +100.0% | Form 10-Q (filed 2025-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 2,600 | +52.9% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2024 | Sep 29, 2024 | 1,800 | – | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,500 | – | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,600 | – | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 1,700 | – | Form 10-K (filed 2024-02-22) ↗ |
Cite this data
StockData. (2026). Pfizer Enterprise Cost Realignment Program (2023–2027) ($M), quarterly Q4 2023–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/restruct-cum-realign
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.